ESMO 2018 | Post hoc KEYNOTE-040 analysis: pembrolizumab for HNSCC produces lasting immune effect

Ezra Cohen

The KEYNOTE-040 study explored the use of pembrolizumab vs. standard treatment for recurrent or metastatic head and neck cancer. At the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, the post hoc analyses of treatment options from this study were presented, as discussed here by Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, speaks at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video